https://www.nasdaq.com/press-release/ascendis-pharma-a-s-to-participate-in-40th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-virtual-rd-program-update-highlights-continued-development-across
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-to-host-virtual-rd-program-update-on-december-14-2021-12-07
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-top-line-results-from-week-84-of-its-phase-2-path
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-to-participate-in-the-evercore-isi-4th-annual-healthconx
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-share-repurchase-program-update-2021-11-15
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-receives-positive-chmp-opinion-for-transcontm-hgh-for-patients
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-third-quarter-2021-financial-results-2021-11-10
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-presents-new-non-clinical-data-for-transcontm-tlr7-8-agonist
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-share-repurchase-program-update-2021-11-08
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-third-quarter-2021-financial-results-and-business
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-u.s.-commercial-launch-of-skytrofar-lonapegsomatropin
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-presentations-for-transcontm-pth-and-transcontm-cnp-at
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-share-repurchase-program-2021-09-29
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-mean-bone-mineral-density-bmd-data-from-phase-2-path
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-upcoming-investor-presentations-2021-09-07
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-submits-investigational-new-drug-application-to-initiate
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-pricing-of-public-offering-of-adss-2021-09-01
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-proposed-public-offering-of-adss-2021-08-31
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-second-quarter-2021-financial-results-2021-08-25
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-u.s.-food-and-drug-administration-approval-of-skytrofar
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-second-quarter-2021-financial-results-and-business
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-upcoming-investor-presentations-in-august-2021-08-06
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-target-enrollment-achieved-in-the-phase-3-pathway-trial
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-extension-of-u.s.-food-and-drug-administration-review
https://www.nasdaq.com/press-release/the-first-hormone-replacement-therapy-for-hypoparathyroidism-in-china-obtains-ind
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-invites-the-public-to-attend-a-story-of-courage%3a-living-with
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-first-quarter-2021-financial-results-2021-05-27
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-first-quarter-2021-financial-results-and-business
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-expansion-of-global-clinical-reach-for-transcontm-pth
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-preliminary-58-week-results-from-open-label-extension
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-presentations-for-transcontm-pth-at-upcoming-medical
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-at-the-bofa-securities-2021-virtual
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-presentations-for-transcontm-hgh-at-upcoming-medical
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-at-the-j.p.-morgan-10th-annual-napa
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-presents-6-month-open-label-extension-data-from-phase-2-path
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-at-oppenheimer-31st-annual-healthcare
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-full-year-2020-financial-results-2021-03-10
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-seven-presentations-at-endo-2021-demonstrating
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-full-year-2020-financial-results-and-business-update
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-new-outgrow-ghd-educational-resource-to-support-rare
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-at-svb-leerink-10th-annual-global
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-provides-vision-3x3-update-at-39th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/visen-pharmaceuticals-closes-%24150-million-series-b-financing-to-accelerate-the
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-equity-investment-in-visen-pharmaceuticals-2021-01-08
https://www.nasdaq.com/press-release/visen-pharmaceuticals-receives-ind-approval-to-initiate-phase-2-clinical-trial-of
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-in-39th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-filing-of-investigational-new-drug-application-to
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-planned-board-transition-2020-12-14
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-at-the-evercore-isi-3rd-annual-healthconx
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-to-host-virtual-oncology-rd-day-on-friday-november-20-2020-11-11
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-third-quarter-2020-financial-results-2020-11-11
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-appoints-dr.-mark-a.-bach-as-senior-vice-president-of-clinical
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-third-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-receives-orphan-designation-for-transcontm-pth-for-treatment-of
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-presentations-for-its-endocrinology-rare-disease
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-preliminary-six-month-data-from-open-label-extension-of
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-filing-of-the-clinical-trial-notification-for-phase-3
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-support-for-childrens-growth-awareness-week-and-day
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-at-the-18th-annual-morgan-stanley-virtual
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-presentations-for-transcontm-pth-and-0
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-submits-marketing-authorisation-application-maa-to-the-european
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-u.s.-food-and-drug-administration-fda-accepts-biologics
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-presentations-for-transcontm-pth-and-hypoparathyroidism
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-at-the-2020-wells-fargo-virtual
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-second-quarter-2020-financial-results-and-announces-new
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-second-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-receives-orphan-designation-for-transcontm-cnp-for-the-treatment
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-upcoming-investor-presentations-in-august-2020-08-04
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-pricing-of-public-offering-of-adss-2020-07-07
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-proposed-public-offering-of-adss-2020-07-06
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-receives-positive-opinion-from-the-paediatric-committee-of-the
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-submission-of-biologics-license-application-bla-to-fda
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-presentation-of-preclinical-data-for-transcon-il-2-b-g
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-in-endo-online-2020-2020-06-08
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-first-quarter-2020-financial-results-2020-05-19
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-will-appoint-jesper-hoiland-as-global-chief-commercial-officer
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-first-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-top-line-data-from-fixed-dose-portion-of-phase-2-trial
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-receives-orphan-drug-designation-for-transcontm-hgh-as-treatment
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-full-year-2019-financial-results-2020-04-01
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-full-year-2019-financial-results-and-business-update
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-upcoming-investor-presentation-in-february-2020-02-12
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-provides-pipeline-update-and-reviews-progress-towards-vision-3x3
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-participation-in-38th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-reports-third-quarter-2019-financial-results-2019-11-18
https://www.nasdaq.com/press-release/ascendis-pharma-expands-transcontm-pth-phase-2-path-forward-clinical-trial-to
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-upcoming-investor-presentation-in-november-2019-11-08
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-first-presentation-of-preclinical-data-utilizing
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-third-quarter-2019-financial-results-and-business
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-receives-orphan-designation-for-transcontm-hgh-for-the-treatment
https://www.nasdaq.com/press-release/ascendis-pharma-a-s-announces-upcoming-investor-presentation-in-october-2019-09-26
